1887

Journal of Medical Microbiology logo

Volume 57, Issue 4

Synergistic activity of azoles with amiodarone against clinically resistant tested by chequerboard and time–kill methods Free

Abstract

is the most common candidal pathogen, causing serious systemic disease in immunocompromised patients. Azoles are widely applied and largely effective; however, they are generally fungistatic and clinically resistant isolates are emerging increasingly. The present study provided evidence using a chequerboard technique that amiodarone is strongly synergistic with azoles against resistant , with mean fractional inhibitory concentration indices of 0.01 and high-percentage synergistic interactions of 1250 %. A time–kill study performed by both colony counting and a colorimetric reduction assay confirmed the synergistic interaction, with a ≥2 log decrease in c.f.u. ml compared with the corresponding azoles alone. These results suggest the possibility of supplementing azoles with amiodarone to treat resistant infections.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): AMD, amiodarone , BI, Bliss independence , CI, confidence interval , FIC, fractional inhibitory concentration , FICI, FIC index , FLC, fluconazole , ITC, itraconazole , LA, Loewe additivity , VRC, voriconazole and XTT, 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47651-0
2008-04-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/4/457.html?itemId=/content/journal/jmm/10.1099/jmm.0.47651-0&mimeType=html&fmt=ahah

References

  1. Afeltra J., Vitale R. G., Mouton J. W., Verweij P. E. 2004; Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother 48:1335–1343 [CrossRef]
     [Google Scholar]
  2. Andes D., Forrest A., Lepak A., Nett J., Marchillo K., Lincoln L. 2006; Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans . Antimicrob Agents Chemother 50:2374–2383 [CrossRef]
     [Google Scholar]
  3. Barchiesi F., Di Francesco L. F., Compagnucci P., Arzeni D., Giacometti A., Scalise G. 1998; In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans . J Antimicrob Chemother 41:59–65
     [Google Scholar]
  4. Baumgartner C., Freydiere A. M., Gille Y. 1996; Direct identification and recognition of yeast species from clinical material by using albicans ID and CHROMagar Candida plates. J Clin Microbiol 34:454–456
     [Google Scholar]
  5. CLSI 2002 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts . Approved standard M27–A2 Wayne, PA: Clinical Laboratory Standards Institute;
     [Google Scholar]
  6. Courchesne W. E. 2002; Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther 300:195–199 [CrossRef]
     [Google Scholar]
  7. Cruz M. C., Goldstein A. L., Blankenship J. R., Del Poeta M., Davis D., Cardenas M. E., Perfect J. R., McCusker J. H., Heitman J. 2002; Calcineurin is essential for survival during membrane stress in Candida albicans . EMBO J 21:546–559 [CrossRef]
     [Google Scholar]
  8. Espinel-Ingroff A., Barchiesi F., Cuenca-Estrella M., Pfaller M. A., Rinaldi M., Rodriguez-Tudela J. L., Verweij P. E. 2005a; International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43:3884–3889 [CrossRef]
     [Google Scholar]
  9. Espinel-Ingroff A., Barchiesi F., Cuenca-Estrella M., Fothergill A., Pfaller M. A., Rinaldi M., Rodriguez-Tudela J. L., Verweij P. E. 2005b; Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol 43:4535–4540 [CrossRef]
     [Google Scholar]
  10. Filler S. G., Sheppard D. C. 2006; Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2:e129 [CrossRef]
     [Google Scholar]
  11. Fricker-Hidalgo H., Vandapel O., Duchesne M. A., Mazoyer M. A., Monget D., Lardy B., Lebeau B., Freney J., Ambroise-Thomas P., Grillot R. 1996; Comparison of the new API Candida system to the ID 32C system for identification of clinically important yeast species. J Clin Microbiol 34:1846–1848
     [Google Scholar]
  12. Ghannoum M. A., Fu Y., Ibrahim A. S., Mortara L. A., Shafiq M. C., Edwards J. E. Jr, Criddle R. S. 1995; In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans . Antimicrob Agents Chemother 39:2459–2465 [CrossRef]
     [Google Scholar]
  13. Girmenia C., Venditti M., Martino P. 2003; Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagn Microbiol Infect Dis 46:227–231 [CrossRef]
     [Google Scholar]
  14. Gupta S. S., Ton V. K., Beaudry V., Rulli S., Cunningham K., Rao R. 2003; Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 278:28831–28839 [CrossRef]
     [Google Scholar]
  15. Klepser M. E., Ernst E. J., Lewis R. E., Ernst M. E., Pfaller M. A. 1998; Influence of test conditions on antifungal time–kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 42:1207–1212
     [Google Scholar]
  16. Kuhn D. M., Chandra J., Mukherjee P. K., Ghannoum M. A. 2002; Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 70:878–888 [CrossRef]
     [Google Scholar]
  17. Kuhn D. M., Balkis M., Chandra J., Mukherjee P. K., Ghannoum M. A. 2003; Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 41:506–508 [CrossRef]
     [Google Scholar]
  18. Lewis R. E., Kontoyiannis D. P. 2005; Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56:887–892 [CrossRef]
     [Google Scholar]
  19. Meletiadis J., Mouton J. W., Meis J. F., Verweij P. E. 2003; In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47:106–117 [CrossRef]
     [Google Scholar]
  20. Morschhäuser J. 2002; The genetic basis of fluconazole resistance development in Candida albicans . Biochim Biophys Acta 1587:240–248 [CrossRef]
     [Google Scholar]
  21. Mukherjee P. K., Sheehan D. J., Hitchcock C. A., Ghannoum M. A. 2005; Combination treatment of invasive fungal infections. Clin Microbiol Rev 18:163–194 [CrossRef]
     [Google Scholar]
  22. Nicolay J. P., Bentzen P. J., Ghashghaeinia M., Wieder T., Lang F. 2007; Stimulation of erythrocyte cell membrane scrambling by amiodarone. Cell Physiol Biochem 20:1043–1050 [CrossRef]
     [Google Scholar]
  23. Odds F. C. 2003; Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1 [CrossRef]
     [Google Scholar]
  24. Pfaller M. A., Houston A., Coffmann S. 1996; Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans , Candida tropicalis , Candida krusei and Candida ( Torulopsis ) glabrata . J Clin Microbiol 34:58–61
     [Google Scholar]
  25. Pfaller M. A., Boyken L., Hollis R. J., Messer S. A., Tendolkar S., Diekema D. J. 2005; In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans , and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 43:3807–3810 [CrossRef]
     [Google Scholar]
  26. Quan H., Cao Y. Y., Xu Z., Zhao J. X., Gao P. H., Qin X. F., Jiang Y. Y. 2006; Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob Agents Chemother 50:1096–1099 [CrossRef]
     [Google Scholar]
  27. Ramage G., Vande Walle K., Wickes B. L., López-Ribot J. L. 2001; Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45:2475–2479 [CrossRef]
     [Google Scholar]
  28. Ribeiro M. A., Paula C. R. 2007; Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?. Diagn Microbiol Infect Dis 57:71–75 [CrossRef]
     [Google Scholar]
  29. Tam V. H., Schilling A. N., Lewis R. E., Melnick D. A., Boucher A. N. 2004; Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48:4315–4321 [CrossRef]
     [Google Scholar]
  30. Te Dorsthorst D. T., Verweij P. E., Meis J. F., Punt N. C., Mouton J. W. 2002; Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother 46:702–707 [CrossRef]
     [Google Scholar]
  31. Te Dorsthorst D. T., Verweij P. E., Meis J. F., Punt N. C., Mouton J. W. 2004; In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother 48:2007–2013 [CrossRef]
     [Google Scholar]
  32. Vassallo P., Trohman R. G. 2007; Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47651-0
Loading
Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time–kill methods
J. Med. Microbiol. 57, 457 (2008); https://doi.org/10.1099/jmm.0.47651-0
/content/journal/jmm/10.1099/jmm.0.47651-0
/content/journal/jmm/10.1099/jmm.0.47651-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error